These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 24609063

  • 21. Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
    Crépey P, Boiron L, Araujo RR, Lopez JG, Petitjean A, de Albuquerque Luna EJ.
    BMC Public Health; 2020 Sep 09; 20(1):1374. PubMed ID: 32907562
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Cost-Effectiveness and Health Impacts of Different Influenza Vaccination Strategies for Children in China.
    Gong Y, Yao X, Peng J, Ma Y, Fang Y, Yan K, Jiang M.
    Am J Prev Med; 2023 Jul 09; 65(1):155-164. PubMed ID: 37037733
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
    Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM.
    MMWR Recomm Rep; 2022 Aug 26; 71(1):1-28. PubMed ID: 36006864
    [Abstract] [Full Text] [Related]

  • 26. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 27. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
    de Boer PT, Crépey P, Pitman RJ, Macabeo B, Chit A, Postma MJ.
    Value Health; 2016 Dec 15; 19(8):964-975. PubMed ID: 27987647
    [Abstract] [Full Text] [Related]

  • 28. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
    Van Bellinghen LA, Marijam A, Tannus Branco de Araujo G, Gomez J, Van Vlaenderen I.
    Braz J Infect Dis; 2018 Dec 15; 22(1):1-10. PubMed ID: 29352897
    [Abstract] [Full Text] [Related]

  • 29. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.
    Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2013 Sep 20; 62(RR-07):1-43. PubMed ID: 24048214
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 31. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model.
    Van Bellinghen LA, Meier G, Van Vlaenderen I.
    PLoS One; 2014 Jun 02; 9(6):e98437. PubMed ID: 24905235
    [Abstract] [Full Text] [Related]

  • 32. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS, Noh JY, Lee J, Choi JY, Lee JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):587-592. PubMed ID: 28933625
    [Abstract] [Full Text] [Related]

  • 33. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
    National Immunization Advisory Committee Technical Working Group.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct 06; 54(10):1035-1059. PubMed ID: 33131228
    [Abstract] [Full Text] [Related]

  • 34. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season.
    Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J.
    MMWR Recomm Rep; 2024 Aug 29; 73(5):1-25. PubMed ID: 39197095
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Nowalk MP, Smith KJ, Raviotta JM, Wateska A, Zimmerman RK.
    Vaccine; 2024 Oct 24; 42(24):126107. PubMed ID: 38971665
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
    Thommes EW, Ismaila A, Chit A, Meier G, Bauch CT.
    BMC Infect Dis; 2015 Oct 27; 15():465. PubMed ID: 26503131
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial.
    Vesikari T, Virta M, Heinonen S, Eymin C, Lavis N, Chabanon AL, Gresset-Bourgeois V.
    Hum Vaccin Immunother; 2020 Mar 03; 16(3):623-629. PubMed ID: 31526225
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A, Ortiz de Lejarazu R, Reina J, Callejo D, Cuervo J, Morano Larragueta R.
    Hum Vaccin Immunother; 2016 Sep 03; 12(9):2269-77. PubMed ID: 27184622
    [Abstract] [Full Text] [Related]

  • 39. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
    Kim YK, Song JY, Jang H, Kim TH, Koo H, Varghese L, Han E.
    Pharmacoeconomics; 2018 Dec 03; 36(12):1475-1490. PubMed ID: 30251078
    [Abstract] [Full Text] [Related]

  • 40. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
    Greenberg DP, Robertson CA, Talbot HK, Decker MD.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2058-2064. PubMed ID: 28700265
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.